JP2024543147A - 中枢神経系（ｃｎｓ）の脱髄疾患のサトラリズマブによる治療 - Google Patents

中枢神経系（ｃｎｓ）の脱髄疾患のサトラリズマブによる治療 Download PDF

Info

Publication number
JP2024543147A
JP2024543147A JP2024531227A JP2024531227A JP2024543147A JP 2024543147 A JP2024543147 A JP 2024543147A JP 2024531227 A JP2024531227 A JP 2024531227A JP 2024531227 A JP2024531227 A JP 2024531227A JP 2024543147 A JP2024543147 A JP 2024543147A
Authority
JP
Japan
Prior art keywords
antibody
subject
seq
mogad
amino acid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2024531227A
Other languages
English (en)
Japanese (ja)
Other versions
JP2024543147A5 (https=
Inventor
孝俊 小澤
舞 山城
創 伊藤
俊介 吉田
ジリアン スミス
イヴァナ ヴォドピーヴェッツ
シアン レノン－クライムズ
ガエル クリンゲルシュミット
ビューディンゲン ハンス－クリスチャン フォン
バウマン ハンナ シルバー
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
F Hoffmann La Roche AG
Original Assignee
F Hoffmann La Roche AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by F Hoffmann La Roche AG filed Critical F Hoffmann La Roche AG
Publication of JP2024543147A publication Critical patent/JP2024543147A/ja
Publication of JP2024543147A5 publication Critical patent/JP2024543147A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Transplantation (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
JP2024531227A 2021-11-26 2022-10-25 中枢神経系（ｃｎｓ）の脱髄疾患のサトラリズマブによる治療 Pending JP2024543147A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
PCT/JP2021/043459 WO2023095305A1 (en) 2021-11-26 2021-11-26 Treatment of a demyelinating disease of the central nervous system (cns) with satralizumab
JPPCT/JP2021/043459 2021-11-26
PCT/JP2022/039605 WO2023095510A1 (en) 2021-11-26 2022-10-25 Treatment of a demyelinating disease of the central nervous system (cns) with satralizumab

Publications (2)

Publication Number Publication Date
JP2024543147A true JP2024543147A (ja) 2024-11-19
JP2024543147A5 JP2024543147A5 (https=) 2025-10-30

Family

ID=86539186

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2024531227A Pending JP2024543147A (ja) 2021-11-26 2022-10-25 中枢神経系（ｃｎｓ）の脱髄疾患のサトラリズマブによる治療

Country Status (10)

Country Link
US (1) US20250034265A1 (https=)
JP (1) JP2024543147A (https=)
KR (1) KR20240107372A (https=)
CN (1) CN118591389A (https=)
AU (1) AU2022398430A1 (https=)
CA (1) CA3238940A1 (https=)
IL (1) IL313058A (https=)
MX (1) MX2024006393A (https=)
TW (1) TW202330030A (https=)
WO (3) WO2023095305A1 (https=)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN104761637B (zh) 2006-03-31 2021-10-15 中外制药株式会社 调控抗体血液动力学的方法
ES2595638T3 (es) 2007-09-26 2017-01-02 Chugai Seiyaku Kabushiki Kaisha Método para modificar el punto isoeléctrico de un anticuerpo mediante la sustitución de aminoácidos en una CDR
WO2018203545A1 (ja) 2017-05-02 2018-11-08 国立研究開発法人国立精神・神経医療研究センター Ｉｌ－６及び好中球の関連する疾患の治療効果の予測及び判定方法
WO2019151418A1 (ja) 2018-01-31 2019-08-08 元一 加藤 Ｉｌ－６阻害剤を含有する喘息の治療剤
EP3957324A4 (en) 2019-04-17 2023-02-08 Hiroshima University THERAPEUTIC FOR UROLOGICAL ONCOLOGY CHARACTERIZED BY BEING ADMINISTRATED IN COMBINATION WITH IL-6 INHIBITOR AND CCR2 INHIBITOR
EP4159236A4 (en) 2020-05-29 2024-08-21 Chugai Seiyaku Kabushiki Kaisha Antibody-containing formulation

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2010003329A (es) 2007-09-26 2010-04-27 Chugai Pharmaceutical Co Ltd Anticuerpo anti-receptor de il-6.
TWI440469B (zh) * 2008-09-26 2014-06-11 Chugai Pharmaceutical Co Ltd Improved antibody molecules
WO2010065116A2 (en) 2008-12-02 2010-06-10 The Trustees Of The University Of Pennsylvania The use of il-27-p28 to antagonize il-6 mediated signaling
CA2972393A1 (en) 2015-02-27 2016-09-01 Chugai Seiyaku Kabushiki Kaisha Composition for treating il-6-related diseases

Also Published As

Publication number Publication date
CA3238940A1 (en) 2023-06-01
WO2023095852A1 (en) 2023-06-01
TW202330030A (zh) 2023-08-01
MX2024006393A (es) 2024-06-04
IL313058A (en) 2024-07-01
WO2023095510A1 (en) 2023-06-01
US20250034265A1 (en) 2025-01-30
WO2023095305A1 (en) 2023-06-01
KR20240107372A (ko) 2024-07-09
CN118591389A (zh) 2024-09-03
AU2022398430A1 (en) 2024-06-13

Similar Documents

Publication Publication Date Title
WO2023095852A1 (en) Treatment of a demyelinating disease of the central nervous system (cns) with satralizumab
US20250127891A1 (en) Treatment of autoimmune encephalitis with satralizumab
Khair et al. Para and post-COVID-19 CNS acute demyelinating disorders in children: a case series on expanding the spectrum of clinical and radiological characteristics
Duchow et al. Emerging drugs for the treatment of neuromyelitis optica
CN121152807A (zh) 使用抗cd40l抗体治疗多发性硬化症
US20230322942A1 (en) Methods for treating multiple sclerosis with ocrelizumab
JP2022501378A (ja) 視神経脊髄炎の処置のためのエクリズマブ
US20240270842A1 (en) Use of an anti-cd19 antibody to treat myasthenia gravis
HK40107811A (zh) 使用萨特利珠单抗治疗中枢神经系统(cns)的脱髓鞘疾病
WO2023095854A1 (en) Treatment of a demyelinating disease of the central nervous system (cns) with satralizumab
WO2023119638A1 (en) Treatment of a demyelinating disease of the central nervous system (cns) with satralizumab
KR20260022396A (ko) 항-Aβ 프로토피브릴 항체를 사용한 치료 방법
HK40128652A (zh) 用萨特利珠单抗治疗甲状腺眼病
KR20260005947A (ko) 갑상선 안구 질환의 사트랄리주맙에 의한 치료
HK40111127A (zh) 使用萨特利珠单抗治疗自身免疫性脑炎
EA052907B1 (ru) Применение антитела к cd19 для лечения миастении гравис
US20190247503A1 (en) Methods for treating relapsing forms of multiple sclerosis

Legal Events

Date Code Title Description
A80 Written request to apply exceptions to lack of novelty of invention

Free format text: JAPANESE INTERMEDIATE CODE: A80

Effective date: 20240717

Free format text: JAPANESE INTERMEDIATE CODE: A801

Effective date: 20240717

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20251022

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20251022